<DOC>
	<DOCNO>NCT02864901</DOCNO>
	<brief_summary>This study Phase 2 two-armed placebo-controlled , double-blind , randomize ( 1:1 ) , multiple dose , single center study evaluate safety proof concept chew gum formulation 3 time per day 4 treatment day .</brief_summary>
	<brief_title>A Double-Blind , Randomized , Placebo Controlled , Clinical Trial Antiplaque Chewing Gum ( 30 mg ) - Phase 2 Proof Concept Generally Healthy Patient Population</brief_title>
	<detailed_description />
	<criteria>A negative urine pregnancy test ( female childbearing potential ) A negative urine drug test On reliable form birth control least 30 day prior start study willing use reliable form contraception duration study ( Females childbearing potential ) , reliable contraception define : Abstinence customary lifestyle choice Oral contraceptive , either estrogen progesterone combine , progesterone alone Injectable progesterone Implants levonorgestrel Estrogenic vaginal ring Percutaneous contraceptive patch Intrauterine device intrauterine system Double barrier method [ condom occlusive cap ( diaphragm cervical vault cap ) plus spermicidal agent ( foam , gel , film , cream , suppository ) ] Male partner sterilization least 6 month prior female subject 's entry study , male sole partner subject Postmenopausal least two year Good health , determine pertinent medical history , physical examination , vital sign A minimum 20 natural teeth 6 scorable surface per tooth Sufficient number oppose posterior teeth chew side mouth determined examine dentist Teeth gross caries , full crown extensive restoration facial and/or lingual surface , orthodontic band , third molar include tooth count Subject must refrain oral hygiene procedure 12 16 hour prior screen visit Plaque Index 1.95 great ( Turesky et al1970 ) Willing forgo optional dental procedure study period , dental prophylaxis teeth whiten Ability comprehend willingness sign inform consent , include Authorization Release Health Information document Ability access internet complete drug compliance information Willingness comply study procedure E01 Phenylketonuria E02 Acute chronic medical condition , organ system disease , medication , principal investigator 's opinion , would impair subject 's ability participate E03 TMD E04 Selfreported allergy sucralose mint flavor E05 Selfreported use tobacco product include ecigarettes E06 Use type anticoagulant medication ( eg clopidogrel ) E07 Routine use proton pump inhibitor E08 Allergic component study drug E09 Gross oral pathology , include widespread caries chronic neglect , extensive restoration , preexist gross plaque calculus , soft hard tissue tumor oral cavity E010Orthodontic appliance removable partial denture compromise ability potential subject participate study E011Periodontitis indicate periodontal pocket great 4 millimeter one site E012 Receipt investigational drug/test product within 30 day prior study entry study entry define Day 0 , currently participate either active followup phase investigational study plan participate investigational study participation trial E013 Participation Phase 1/2a antiplaque study E014 Receipt antibiotic within 30 day prior study entry E015 Need antibiotic prophylaxis prior invasive dental procedure E016 Receipt prescription antibacterial oral product ( eg product contain chlorhexidine ) within 30 day prior study entry E017 Pregnant breastfeed female E018 An employee study site directly involve study E019 Inability comply assign treatment regimen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>